[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"countryName\":\"Bangladesh\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":720},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,114,0,25,[9,44,76,108,135,162,193,219,250,271,296,315,339,367,395,426,449,482,512,540,575,603,629,657,690],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100053465",false,"NCT07696819","Rationale of Subcutaneous Levofloxacin Infiltration as an Adjunct for Surgical Site Infection Prevention in Emergency Laparotomy","Inclusion Criteria:\n\n* Patients aged 18 years and above\n* Patients undergoing emergency laparotomy for contaminated surgical pathology\n* Patients undergoing emergency laparotomy for dirty\u002Finfected surgical pathology\n\nExclusion Criteria:\n\n* Patients with known hypersensitivity to levofloxacin or other fluoroquinolones\n* Pregnant women or lactating mothers\n* Patients with pre-existing severe renal impairment\n* Patients with pre-existing skin infection at the incision site\n* Patients requiring re-laparotomy within 48 hours","ALL","18 Years",{"count":18,"type":19},90,"ESTIMATED","INTERVENTIONAL",[22],"NA","Surgical site infection (SSI) remains a major cause of postoperative morbidity following emergency laparotomy, particularly in contaminated and dirty\u002Finfected abdominal conditions. Systemic antibiotic prophylaxis alone often fails to achieve adequate local tissue concentrations at the incision site due to impaired perfusion, contributing to persistently high SSI rates in this population.\n\nThis trial evaluates subcutaneous infiltration of levofloxacin, a broad-spectrum fluoroquinolone with favorable tissue penetration, administered along the wound edges immediately prior to skin closure, as an adjunct to standard surgical and antibiotic management.\n\nThis study is investigator-initiated and will be conducted as a single-center trial within the Department of Surgery, Sylhet MAG Osmani Medical College Hospital.",[25],"Surgical Site Infection (SSI)",[27,28,29,30],"Surgical Site Infection","Emergency Laparotomy","Subcutaneous Infiltration","Levofloxacin","NOT_YET_RECRUITING","2026-07-10",{"date":34,"type":35},"2026-07-13","ACTUAL",{"date":37,"type":19},"2026-08-01",{"date":39,"type":19},"2026-10-31",{"name":41,"class":42},"Sylhet M.A.G.Osmani Medical College","OTHER",1,{"id":45,"slug":4,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":15,"minAge":4,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":20,"phases":55,"briefSummary":56,"conditions":57,"keywords":62,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":43},"100637574","NCT07620613","Perinatal Mortality Outcomes Through Household Infection Pathways","Effect of Cement Floors on Perinatal and Neonatal Mortality in Bangladesh: a Randomized Trial in Rural Bangladesh","POTH","Inclusion Criteria:\n\n* Prior enrollment in the CRADLE trial (NCT05372068), in either arm, and currently residing in the original CRADLE-enrolled household\n* Residence in Sirajganj or Tangail districts in Bangladesh\n* No major non-compliance (e.g., no removal of concrete floor in intervention arm or installation of concrete floor in control arm)\n* No plan to relocate within the study follow-up period\n* Incident pregnancy occurring after CRADLE trial enrollment, confirmed after 26 weeks gestation",true,"6 Years",{"count":54,"type":19},196,[22],"The goal of this trial is to learn if replacing household soil floors with concrete floors can prevent deaths of infants around the time of birth, including stillbirths and deaths in the first month of life in rural Bangladesh. The primary question the study aims to answer is: Does residing in a home with a concrete vs. soil floor reduce the perinatal and neonatal morality in index children and their younger siblings up to 6 years post-installation of concrete floors?\n\nResearchers will compare participants in households with concrete floors (intervention) vs. soil floors (comparison group) to see if concrete floors reduce the rate of perinatal death and child death up the 6 years post-intervention.\n\nThis study will extend an ongoing NIH-funded randomized trial in which households with soil floors where a pregnant woman resided were randomly chosen to receive a concrete floor intervention or to retain their existing soil floor. This study will track pregnancies, births, and deaths among infants born to pregnant mothers in the original study to measure effects of household concrete flooring up to 6 years after the concrete floors were installed.",[58,59,60,61],"Stillbirth and Neonatal Mortality","Perinatal Mortality","Infant Mortality","Child Mortality",[63,64,65,66],"concrete floor","soil floor","dirt floor","housing intervention","2026-06-27",{"date":69,"type":35},"2026-07-01",{"date":71,"type":19},"2026-06-01",{"date":73,"type":19},"2029-05-01",{"name":75,"class":42},"Stanford University",{"id":77,"slug":4,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":20,"phases":86,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":107},"100581807","NCT06855108","Caffeine for Hypoxic Ischemic Encephalopathy","Caffeine for Hypoxic Ischemic Encephalopathy (CHIME Trial)","CHIME","Participant Inclusion Criteria:\n\nInfants who meet all the following criteria are eligible for enrollment as study participants:\n\n1. Liveborn infants ≥36 weeks\n2. Birth weight ≥1800 grams\n3. Meets physiologic criteria for moderate to severe HIE, defined as meeting either of the following two criteria:\n\n   1. Criterion #1: Severe acidosis, defined as an umbilical cord sample or neonatal serum sample within one hour after birth demonstrating any of following criteria:\n\n      * pH \\\u003C7.0; or\n      * Base Deficit ≥16 mmol\u002FL; or\n      * Lactate \\>8 mmol\u002FL.\n   2. Criterion #2: Participant must meet all of the following three criteria:\n\n   i. Moderate acidosis, defined as an umbilical cord sample or neonatal serum sample within one hour after birth demonstrating any of following criteria:\n   * POC pH 7.0-7.15; or\n   * Base Deficit 10.0-15.9 mmol\u002FL; or\n   * Lactate 6-8 mmol\u002FL.\n\n   ii. Evidence of an acute perinatal event (i.e., placental abruption, intrapartum hemorrhage, cord prolapse, severe fetal heart rate abnormality, uterine rupture).\n\n   iii. Any of the following criteria:\n   * 10-minute Apgar \\\u003C5; or\n   * Need for assisted ventilation initiated at birth and continued for ≥10 minutes\n4. Meets neurologic criteria for moderate to severe HIE, defined as a physical exam conducted between one and six hours after birth that meets either of the following criteria:\n\n   1. Moderate to severe encephalopathy in at least three out of six modified Sarnat categories (level of consciousness, spontaneous activity, muscle tone, posture, primitive reflexes, autonomic function); or\n   2. A clinical diagnosis of seizure in the first six hours after birth.\n\nParticipant Exclusion Criteria:\n\nInfants who meet any of the following criteria are not eligible for enrollment as study participants:\n\n1. Home births\n2. Infants who cannot be enrolled, randomized and receive study medication within 6 hours post-delivery\n3. Infants with a recognized major congenital anomaly or genetic syndrome that would affect their neurodevelopment.\n4. Infants for whom medical care will not be provided based on the severity of their condition or any other condition that would preclude participation per clinical judgement.\n5. Infant has received therapeutic hypothermia or there is a clinical plan to initiate active or passive hypothermia for the infant.\n6. Infants who will be unavailable to complete follow-up visits.\n7. Infants who have received caffeine after delivery.\n8. Infants whom the health care team deem ineligible for the study based on likelihood to receive caffeine outside of the study protocol.\n9. Enrollment in another trial that will impact participation in this trial.","6 Hours",{"count":85,"type":19},830,[87],"PHASE3","CHIME is a randomized, parallel-arm, double-blind, placebo-controlled trial focused on infants with hypoxic ischemic encephalopathy (HIE). The trial will recruit neonates who are diagnosed with HIE within six hours after birth based on physiologic criteria (acidosis noted on an umbilical cord or early \\[\\\u003C1 hour\\] postnatal blood sample) and neurologic criteria (modified Sarnat exam consistent with encephalopathy). Following informed consent, and by six hours after birth, neonates with HIE will be randomized to one of two treatment arms and subsequently receive one 20 mg\u002Fkg dose of oral caffeine followed by two additional 10 mg\u002Fkg doses at 24-hour intervals or placebo of the same regimen (three total doses).\n\nThe goal of this clinical trial is to compare the incidence of all-cause mortality OR moderate to severe neurodevelopmental impairment (NDI) at 18-22 months between neonates with HIE who are randomized to oral caffeine or placebo. Our hypothesis is that neonates with HIE who receive oral caffeine will have 10% lower incidence of all-cause mortality or moderate to severe NDI at 18-22 months compared to placebo.",[90],"Hypoxic Ischemic Encephalopathy (HIE)",[92,93,94,95],"Caffeine","Hypoxic Ischemic Encephalopathy","HIE","AKI","RECRUITING","2026-06-19",{"date":99,"type":35},"2026-06-24",{"date":101,"type":35},"2026-04-08",{"date":103,"type":19},"2030-07",{"name":105,"class":106},"NICHD Global Network for Women's and Children's Health","NETWORK",7,{"id":109,"slug":4,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":20,"phases":117,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":131,"leadSponsor":133,"locationsCount":43},"100641611","NCT07655700","Comparison of Propranolol, Flunarizine and Their Combination in Preventing Migraine in Adults in a Tertiary Care Hospital in Bangladesh","Comparative Efficacy of Propranolol, Flunarizine, and Their Combination in Migraine Prophylaxis: An Open-label Parallel-arm Randomized Controlled Trial","Inclusion Criteria:\n\n1. Participants aged 18 to 55 years.\n2. Diagnosis of episodic migraine, defined according to the International Classification of Headache Disorders, 3rd edition (ICHD-3) criteria.\n3. Participants experiencing 4 or more migraine attacks per month.\n4. Willingness to provide written informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Comorbidities:\n\n   * Presence of other primary headache disorders, chronic migraine, hemiplegic migraine, basilar migraine or any secondary headache disorder.\n   * Known serious underlying systemic diseases including Cardiac disease (Heart failure, Heart Block, Arrhythmia), Renal dysfunction, Liver dysfunction, Pulmonary disease (Asthma, COPD), Peripheral vascular disease, Extrapyramidal disease (Parkinson disease, Chorea, Dystonia).\n   * Pregnancy or breastfeeding.\n   * Psychiatric illness (Depression, Psychosis, Obsessive compulsive disorder).\n2. Medications:\n\n   * Received migraine prophylactic medication within 60 days prior to screening.\n   * Use of specific contraindicated medications, including beta-blockers or calcium channel blockers, except as part of the study treatments.\n3. Non-compliance:\n\n   * Inability or unwillingness to comply with study protocols, including maintaining a headache diary or attending follow-up visits.\n4. History of Allergies:\n\n   * Known hypersensitivity to propranolol, flunarizine\n5. Substance Use:\n\n   * Current substance abuse","55 Years",{"count":116,"type":19},177,[118],"PHASE4","Migraine is a common and disabling neurological condition that affects quality of life, work productivity, and daily functioning. In Bangladesh, migraine is a major health problem, yet access to effective and affordable preventive treatments remains limited. Preventive (prophylactic) treatment is recommended for people who experience frequent migraine attacks in order to reduce the number, severity, and duration of headaches.\n\nPropranolol and flunarizine are two commonly used and relatively inexpensive medications for migraine prevention. Both drugs have been shown to reduce migraine frequency when used alone. However, some patients do not respond adequately to a single medication. Using a combination of drugs that work through different mechanisms may improve treatment effectiveness without significantly increasing side effects. There is limited local evidence comparing propranolol, flunarizine, and their combination in migraine prevention, particularly in the Bangladeshi population.\n\nThis study is designed to compare the effectiveness and safety of propranolol alone, flunarizine alone, and a combination of propranolol and flunarizine in preventing episodic migraine in adults. The main hypothesis is that at least one of these treatment strategies, particularly combination therapy, may be more effective than the others in reducing migraine burden.\n\nThis is an open-label, parallel-arm, randomized controlled trial conducted at Chittagong Medical College Hospital, Bangladesh. A total of 177 adult patients aged 18 to 55 years who are diagnosed with episodic migraine and experience four or more migraine attacks per month will be enrolled. Participants will be randomly assigned to one of three treatment groups: propranolol, flunarizine, or a combination of both medications. Treatment will be given for 12 weeks, with dose adjustments during the first week and follow-up visits at 6 and 12 weeks.\n\nThe primary outcome of the study is the reduction in the number of monthly migraine days. Secondary outcomes include the proportion of patients achieving at least a 50% reduction in migraine days, changes in headache severity and duration, improvement in migraine-related disability (measured by the Migraine Disability Assessment Score), patient-reported treatment satisfaction, and the frequency of side effects.\n\nThe results of this study are expected to provide important local evidence to guide clinicians in selecting effective and affordable migraine preventive treatments and to clarify whether combination therapy offers additional benefits over single-drug therapy in routine clinical practice.",[121],"Migraine Prophylaxis",[121,123,124,125,126],"Randomized Controlled Trial","Combination Therapy","Propranolol","Flunarizine","2026-06-17",{"date":129,"type":35},"2026-06-22",{"date":69,"type":19},{"date":132,"type":19},"2027-04-30",{"name":134,"class":42},"Chittagong Medical College",{"id":136,"slug":4,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":20,"phases":143,"briefSummary":144,"conditions":145,"keywords":149,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":43},"100642090","NCT07653906","Coeliac Plexus vs Splanchnic Nerve Neurolysis for Upper Abdominal Cancer Pain","Effect of Coeliac Plexus Versus Splanchnic Nerve Neurolysis in Pain Management With Upper Abdominal Malignancies","Inclusion Criteria:\n\n* Adult patient\n* Both genders\n* Diagnosed case of upper abdominal malignancy (pancreatic, gastric, hepatic, or biliary origin)\n* Experiencing moderate to severe pain (≥5 on a 10 point visual analog scale)\n* Patients who are conscious and can communicate\n* No Contraindication for nerve block (e.g., coagulopathy, anticoagulant drugs)\n\nExclusion Criteria:\n\n* Previous coeliac plexus block, splanchnic nerve block, or major abdominal nerve ablation\n* Severe spinal deformities or anatomical distortion at the coeliac plexus or splanchnic nerve site\n* Local or systemic infection at or near the block site\n* Known allergy to local anesthetics or neurolytic agents\n* Pregnancy\n* Lactating mother\n* Cognitive impairment or psychiatric illness",{"count":142,"type":19},44,[22],"The goal of this clinical trial is to determine whether Neurolytic Splanchnic Nerve Block (NSNB) reduces pain in adults with upper abdominal malignancies. It will also evaluate the safety of Neurolytic Splanchnic Nerve Block (NSNB). The main questions it aims to answer are:\n\nDoes NSNB reduce pain intensity compared to Neurolytic Coeliac Plexus Block (NCPB), as measured by the Visual Analog Scale (VAS)? What adverse effects do participants experience when receiving Neurolytic Splanchnic Nerve Block (NSNB)?\n\nInvestigators will compare Neurolytic Splanchnic Nerve Block (NSNB) with Neurolytic Coeliac Plexus Block (NCPB) to determine which intervention provides more effective and safer pain relief.\n\nParticipants will:\n\n* receive either NSNB or NCPB under fluoroscopic guidance\n* be monitored immediately and for 2 hours after the procedure for any complications Have their pain intensity recorded immediately after the procedure, and at 7 days, 1 month, and 3 months\n* be evaluated for quality-of-life using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 3 (EORTC QLQ-C30) at 1 month and 3 months.\n* have their opioid consumption tracked throughout the study.",[146,147,148],"Abdominal Neoplasms","Pain Management","Neurolytic Techniques",[150,151,152,153],"Upper abdominal cancer","Splanchnic nerve block","Coeliac plexus block","Analgesic efficacy","2026-06-12",{"date":127,"type":35},{"date":157,"type":35},"2026-05-01",{"date":159,"type":19},"2027-01-31",{"name":161,"class":42},"Bangladesh Medical University",{"id":163,"slug":4,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":168,"minAge":16,"maxAge":169,"enrollmentInfo":170,"targetDuration":4,"studyType":20,"phases":172,"briefSummary":173,"conditions":174,"keywords":179,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":43},"100538777","NCT06295250","ASHA Bangladesh--An Integrated Intervention to Address Poverty and Depression","ASHA Bangladesh--An Integrated Intervention to Address Depression in Low Income Rural Women","Inclusion Criteria:\n\n1. Age 18-45\n2. Meets criteria for Economic Vulnerability as measured by: household income \\\u003C= 15000 Taka per month; food insufficiency in household over previous six months; OR owning \\\u003C= 10 decimals of land\n3. Family willingness to participate in the program\n4. Basic literacy as measured by ability to read a simple sentence;\n5. A score \\>=10 on the Patient Health Questionnaire (PHQ-9 Depression Scale) at baseline\n\nExclusion Criteria:\n\n1. Pregnancy at screen;\n2. Cognitive or physical impairment precluding participation\n3. Plans to relocate or to travel for \\> 1 month during 18 M period.\n4. Household debt greater than 70,000 Taka","FEMALE","45 Years",{"count":171,"type":19},600,[22],"The goal of this randomized controlled trial is to compare the impact of an integrated intervention combining poverty alleviation and depression treatment to depression treatment alone, in low income rural Bangladeshi women with depression. The main question\\[s\\] it aims to answer are whether adding poverty alleviation to depression treatment in an integrated intervention: 1) improves depression outcomes at 6 months post baseline as measured by changes in the PHQ-9 from baseline--compared to depression treatment alone; 2) reduces the chance of relapse (PHQ-9 \\>=5) at 18 months among patients who remitted (PHQ-9\\\u003C5) at six months--compared to depression treatment alone; and 2) whether adding poverty alleviation to depression treatment improves implementation outcomes including treatment uptake and retention--compared to depression treatment alone. Other outcomes that will be studied include economic vulnerability and psychosocial variables such as anxiety, culturally specific symptoms, quality of life, and function. Participants in both arms will participate in research interviews at 6,12 and 18 months. The project also includes a mixed methods implementation evaluation. Quantitative implementation outcomes to be examined include adoption\u002Fuptake; retention in the intervention, and fidelity of intervention delivery. A qualitative process evaluation will include interviews with 80 study participants and approximately 40 staff members, including research staff, agricultural officers, and interventionist staff.",[175,176,177,178],"Depression","Economic Vulnerability","Anxiety","Culture Specific Symptoms",[180,181,182,183],"Depression treatment","Cash Transfer","Problem Management Plus","Poverty Alleviation","2026-06-11",{"date":186,"type":35},"2026-06-15",{"date":188,"type":35},"2024-03-01",{"date":190,"type":19},"2026-12",{"name":192,"class":42},"University of Massachusetts, Worcester",{"id":194,"slug":4,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":51,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":202,"phases":4,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":215,"leadSponsor":217,"locationsCount":43},"100643532","NCT07602920","Gut Leakage' in Dengue","Gut Leakage and Sonographic Abdominal Changes in Hospitalized Dengue Patients: an Observational Study","GLiD","Inclusion Criteria:\n\nDengue participants\n\n* Participant\u002F legally authorised representative willing and able to give informed consent for participation in the study.\n* Male or Female, adults ≥18 years\n* Diagnosed as a case of Dengue on the basis of clinical features and positive NS1 antigen and\u002For IgM dengue antibody\n* Hospitalized in medicine or dengue ward in Chittagong Medical College Hospital.\n* Enrolled within 24 hours of hospitalization.\n\nHealthy participants\n\n* Participant\u002F legally authorised representative willing and able to give informed consent for participation in the study.\n* Male or Female, adults ≥18 years\n* Clinically healthy with no acute or chronic illness\n* Attendant of a dengue patient (not a patient)\n\nExclusion Criteria:\n\nDengue participants\n\n* Unable to provide consent or participate in follow-up procedures\n* Known chronic gastrointestinal (GI) disease affecting intestinal permeability (IBD, celiac disease), chronic liver disease, active chronic diarrhoea, short bowel loop syndrome, recent (\\\u003C3 months) major GI surgery.\n* Immunosuppression (for example chemotherapy, high-dose steroids), advanced chronic kidney disease, decompensated heart failure.\n* Drugs that can alter the level of biomarkers in blood like metformin, statin, probiotics, steroid within last 48 hours of hospitalization.\n* Pregnancy\n\nHealthy participants\n\n* Unable to provide consent\n* Known chronic gastrointestinal (GI) disease affecting intestinal permeability (IBD, celiac disease), chronic liver disease, active chronic diarrhoea, short bowel loop syndrome, recent (\\\u003C3 months) major GI surgery.\n* Immunosuppression (for example chemotherapy, high-dose steroids), advanced chronic kidney disease, decompensated heart failure.\n* Drugs that can alter the level of biomarkers in blood like metformin, statin, probiotics, steroid within last 48 hours of hospitalization.\n* Pregnancy\n* History of current or recent dengue or other arbo viral infection",{"count":201,"type":19},190,"OBSERVATIONAL","Dengue infections are imposing an increasing global burden of disease, particularly in tropical countries such as Bangladesh. The World Health Organization (WHO) has identified Dengue virus as a priority pathogen for the development of medical counter measures because of the high risk of it causing a Public Health Emergency of Intenational Concern (PHEIC). Warning signs for severe dengue, associated with mortality, include gastrointestinal features including abdominal pain, vomiting, and diarrhoea. Multiple alterations may occur in in the gastrointestinal tract that could lead to damaging of the gastrointestinal wall and gut leakage, the translocation of gut metabolites into the bloodstream. Study team hypothesize that gut leakage initiates inflammatory processes underlying the further development of severe dengue, including features associated with plasma leakage.\n\nThis study aims to investigate intestinal barrier dysfunction (gut leakage) in dengue infection by detecting the translocation of gut-derived bacteria and their products (Lipopolysaccharides, LPS binding protein, sCD14, I-Fatty Acid Binding Protein) into the bloodstream. Study team will recruit hospitalized adult dengue patients (18 years and older) presenting with warning signs or severe disease in a tertiary care public hospital at Chattogram, Bangladesh. Circulating biomarkers indicative of gut permeability and microbial translocation will be measured to assess their presence and association with disease severity.\n\nAbdominal ultrasonography will be performed to characterize gastrointestinal alterations and determine their correlation with biochemical markers of gut leakage and clinical severity. In addition, study team will analyze the gut bacteriome from stool\u002F rectal swab of these patients to explore whether dengue infection induces compositional changes in intestinal microbiota and whether such alterations are linked to gut leakage or disease progression.",[205,206,207,208,209,210],"Dengue","Dengue Hemorrhagic Fever","Intestinal Disease","Ascites","Dengue With Warning Signs","Gut Microbiome","2026-06-08",{"date":213,"type":35},"2026-06-10",{"date":69,"type":19},{"date":216,"type":19},"2028-01-31",{"name":218,"class":42},"University of Oxford",{"id":220,"slug":4,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":224,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":15,"minAge":226,"maxAge":227,"enrollmentInfo":228,"targetDuration":4,"studyType":20,"phases":230,"briefSummary":231,"conditions":232,"keywords":234,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":43},"100620808","NCT07362433","Trial of an AI-enabled Digital Stethoscope to Improve Antibiotic Stewardship","The BLAAAST Trial: Bangladesh Lung Auscultation AI for Antibiotic Stewardship Randomized Controlled Trial","BLAAAST","Inclusion Criteria:\n\n* 2 to 59 months of age (60 days to 59 months 29 days),\n* illness duration 14 days or less,\n* meeting non-severe pneumonia criteria, and\n* from the trial catchment areas.\n\nExclusion Criteria:\n\n* prior participation,\n* age \\\u003C2 months or \\>59 months,\n* illness duration \\>14 days,\n* not meeting IMCI-defined non-severe pneumonia criteria,\n* oxygen saturation (SpO2) \\\u003C90%,\n* moderate or severe malnutrition,\n* known chronic disease,\n* history of prematurity,\n* one or more high risk clinical signs (any WHO-defined clinical danger sign and\u002For WHO-defined emergency sign),\n* known antibiotic exposure in the past 1 week,\n* non-respiratory illness requiring systemic antibiotic treatment according to IMCI guidelines.","2 Months","59 Months",{"count":229,"type":19},2500,[118],"Antibiotics are a mainstay of the treatment of lower respiratory infections in young children even though most episodes are caused by self-limiting viruses. Innovative child friendly tools that improve the diagnosis of respiratory illnesses, safely reduce the unnecessary use of antibiotics, and are suitable for implementation in resource-constrained settings are urgently required to safely improve antibiotic stewardship and stem the rising rates of antibiotic resistance globally.\n\nIn the Bangladesh Lung Auscultation Artificial Intelligence for Antibiotic Stewardship Trial (BLAAAST) the investigators aim to determine whether treatment failure frequency among children in rural Bangladesh managed by clinical guidelines enhanced by a commercially available, artificial intelligence (AI)-enabled digital stethoscope is non-inferior to guidelines alone. The investigators hypothesize treatment failure frequency among 'enhanced IMCI' participants will be no worse than standard care by a +\u002F-2% margin, safely reducing antibiotic use by 50-60%. The investigators will also evaluate if a diagnostic strategy enhanced by an AI-enabled digital stethoscope is a sustainable alternative to standard care for children in rural Bangladesh. The investigators hypothesize that care augmented by an AI-enabled digital stethoscope will have additional benefits via reduced antibiotic use that will outweigh digital auscultation costs resulting in cost-effectiveness compared to current practice.\n\nBLAAAST affords a unique opportunity to evaluate the efficacy of clinical guidelines enhanced by an AI-enabled digital stethoscope on child pneumonia outcomes in Bangladesh, if digital auscultation may be instrumental in the wider antibiotic stewardship strategy, and whether a digital stethoscope diagnostic tool is cost-effective in the care of children with respiratory illnesses.",[233],"Respiratory Infections in Children",[235,236,237,238,239,240,241],"Digital auscultation","Automated digital stethoscope","Artificial intelligence lung sound analysis","Pediatric pneumonia","Integrated Management of Childhood Illness (IMCI)","Antibiotic stewardship","Point-of-care respiratory diagnostics","2026-06-05",{"date":211,"type":35},{"date":245,"type":35},"2026-06-02",{"date":247,"type":19},"2029-06-30",{"name":249,"class":42},"Johns Hopkins University",{"id":251,"slug":4,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":253,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":11,"sex":15,"minAge":255,"maxAge":256,"enrollmentInfo":257,"targetDuration":4,"studyType":20,"phases":259,"briefSummary":261,"conditions":262,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":266,"completionDateStruct":267,"leadSponsor":269,"locationsCount":43},"100638772","NCT07615842","Assessing the Impact of Unnecessary Antibiotic Treatment on the Development of Appropriate Adaptive Immune Responses in Malnourished Bangladeshi Infants","Inclusion Criteria:\n\n* presenting with diarrheal symptoms\n* age under 1 year\n* enrolled in study NCT02764918\n\nExclusion Criteria:\n\n* unwilling to give blood and stool samples","6 Months","48 Months",{"count":258,"type":19},150,[260],"PHASE1","The investigators are examining the role of circulating T follicular helper (Tfh) cells in the induction of the antibody responses. The investigators hypothesize that Tfh cell activation is impaired in Bangladeshi children and that this activation failure is associated with a history of antibiotic use. The results of the investigators' preliminary studies suggest that antibiotic treatment could have a detrimental effect on the development of an appropriate adaptive immune response against Cryptosporidium. Antibiotic treatment for children with cryptosporidiosis, rotavirus and adenovirus 40\u002F41is not currently recommended (supportive therapy only), although usually given to children in Dhaka, Bangladesh. This study will randomly assign children with diarrhea due to Cryptosporidium, rotavirus or adenovirus 40\u002F41 to two groups. Supportive treatment would be provided in both groups, but in group #1, antibiotic treatment would be withheld while group #2 will receive usual care which normally will include antibiotic treatment. The investigators will monitor the children for one year to measure T follicular helper function, antibody production, and reinfection.",[263],"Antibiotic Resistance Prevention","2026-05-29",{"date":71,"type":35},{"date":71,"type":19},{"date":268,"type":19},"2028-06-01",{"name":270,"class":42},"University of Virginia",{"id":272,"slug":4,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":274,"acronym":4,"eligibilityCriteria":275,"healthyVolunteers":51,"sex":15,"minAge":276,"maxAge":277,"enrollmentInfo":278,"targetDuration":4,"studyType":20,"phases":280,"briefSummary":281,"conditions":282,"keywords":285,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":293,"leadSponsor":294,"locationsCount":43},"100640214","NCT07603882","Effects of Emotional Intelligence Training on Marital Satisfaction and Mental Health Among Married People in Dhaka City","Inclusion Criteria:\n\n1. Married men and women living in Dhaka city\n2. Age between 20 and 40 years\n3. Married for at least 2 years and living with spouse\n4. Living in a nuclear family\n5. Able to read and write (literate)\n6. Willing to participate and provide informed consent\n\nExclusion Criteria:\n\n1. Individuals with self-reported severe physical illness\n2. Individuals with incomplete questionnaire responses\n3. Individuals unwilling to participate or unable to provide informed consent","20 Years","60 Years",{"count":279,"type":19},120,[22],"This study aims to examine the effects of Emotional Intelligence (EI) training on marital satisfaction and mental health among married adults in Dhaka city, Bangladesh. Emotional intelligence refers to the ability to recognize, understand, regulate, and manage emotions in oneself and others. Previous studies suggest that emotional intelligence is associated with better relationship quality and psychological well-being; however, limited intervention-based evidence is available in Bangladesh.\n\nA pretest-posttest quasi-experimental design with intervention and control groups will be used. Married adults living in Dhaka City will be assessed on emotional intelligence, marital satisfaction, anxiety, depression, and mental well-being at baseline. Participants with lower emotional intelligence scores based on the baseline TEIQue-SF assessment will be selected for the intervention phase.\n\nThe intervention group will receive a structured emotional intelligence training program focusing on emotional awareness, emotion regulation, empathy, communication skills, and interpersonal problem-solving. Assessments will be conducted at baseline, post-intervention, and follow-up to evaluate changes in marital satisfaction and mental health outcomes.\n\nThe findings are expected to provide evidence regarding the effectiveness of emotional intelligence training as a low-cost, non-clinical intervention for improving marital relationships and psychological well-being among married individuals in Bangladesh.",[283,284],"Emotional Intelligence","Mental Health",[286,287,284,288],"Emotional Intelligence Training","Marital Satisfaction","Psychological Well-being","2026-05-24",{"date":291,"type":35},"2026-05-28",{"date":69,"type":19},{"date":159,"type":19},{"name":295,"class":42},"University of Dhaka",{"id":297,"slug":4,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":302,"targetDuration":4,"studyType":20,"phases":304,"briefSummary":305,"conditions":306,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":312,"leadSponsor":314,"locationsCount":43},"100639573","NCT07598864","\"Dapagliflozin vs Dapagliflozin-Finerenone for Albuminuria in CKD With Type 2 Diabetes\"","Effect of Dapagliflozin Compared to Dapagliflozin-finerenone Combination on Albuminuria in Patients With Chronic Kidney Disease and Type 2 Diabetes: A Randomized Controlled Trial.","Inclusion criteria:\n\nPatients aged ≥ 18 years Patients with T2 DM , as defined by the American Diabetic Association. Urinary ACR ≥ 30 mg\u002Fg and eGFR ≥ 25 ml\u002Fmin per 1.73 m2 Prior treatment with ACEIs or ARBs for more than four weeks up to the maximum tolerated dose Serum potassium ≤ 4.8 mmol\u002FL\n\nExclusion criteria\n\n* Patients with other known causes of proteinuria, e.g. UTI, fever\n* At screening visit SBP higher than 160 mmHg or DBP higher than 100 mmHg or SBP lower than 90 mmHg\n* Glycated hemoglobin (HbA1C) \\>11%\n* Known hypersensitivity to dapagliflozin or finerenone\n* Known case of Addison's disease\n* Known case of hepatic insufficiency\n* Treatment with SGLT2i (empagliflozin:62 hours, dapagliflozin:65hours) or MRAs (finerenone:10-20 hours, spironolactone:7 hours , eplerenone:15-30 hours) within their wash out periods.\n* Patients on non-dihydropyridine Calcium Chanel blockers or Glucagon-like peptide-1 (GLP-1) agonists\n* Pregnant lady or lactating mother",{"count":303,"type":19},88,[87],"Chronic kidney disease (CKD) in patients with type 2 diabetes mellitus (T2DM) is a major cause of morbidity, commonly associated with persistent albuminuria and progressive renal decline. Reducing albuminuria is a key therapeutic goal to slow disease progression. Sodium-glucose cotransporter-2 inhibitors like dapagliflozin and non-steroidal mineralocorticoid receptor antagonists such as finerenone have independently shown significant renoprotective effects. Their combined use may provide additive benefits.\n\nThis open-label randomized controlled trial will be conducted in the Department of Nephrology, Chittagong Medical College Hospital, Bangladesh, including 88 patients with CKD and T2DM. Participants will be randomized into two groups: one receiving dapagliflozin 10 mg plus finerenone 10 mg daily, and the other receiving dapagliflozin 10 mg alone for eight weeks.\n\nThe primary outcome will be the change in urinary albumin-to-creatinine ratio (UACR). Secondary outcomes include serum creatinine, estimated glomerular filtration rate (eGFR), and serum potassium. Safety and adverse events will also be monitored. Data will be analyzed using SPSS version 27.\n\nThis study aims to assess whether combination therapy is more effective than dapagliflozin alone in reducing albuminuria and may help guide treatment strategies in diabetic CKD.",[307],"Diabetic Nephropathy","2026-05-14",{"date":310,"type":35},"2026-05-20",{"date":157,"type":19},{"date":313,"type":19},"2027-05-01",{"name":134,"class":42},{"id":316,"slug":4,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":320,"eligibilityCriteria":321,"healthyVolunteers":51,"sex":15,"minAge":322,"maxAge":323,"enrollmentInfo":324,"targetDuration":4,"studyType":20,"phases":326,"briefSummary":327,"conditions":328,"keywords":329,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":43},"100640714","NCT07591363","Improving Mental Health Through Emotional Intelligence Enhancement","Promoting Mental Health of Secondary School Teachers and Students Through Enhancing Their Emotional Intelligence in Dhaka City","EI-MH","Inclusion Criteria:\n\n* Participants include secondary school students aged 12-17 years and secondary school teachers aged 22-60 years.\n\n  1. students (both boys and girls) enrolled in Classes 7 to 10 in coeducational Bangla-medium secondary schools in Dhaka city;\n  2. teachers (male and female) who taught in these classes;\n  3. teachers who provided informed consent to participate in the training;\n  4. students who provided assent along with parental consent;\n  5. Students identified as belonging to lower EI profiles (e.g., emotionally vulnerable or at-risk groups) based on latent profile analysis (LPA) of Trait Emotional Intelligence scores; and\n  6. individuals who expressed willingness to actively participate in the study.\n\n     \\-\n\n     Exclusion Criteria:\n\n  \u003C!-- -->\n\n  1. individuals with a reported history of severe mental illness;\n  2. individuals with identifiable visual, hearing, or physical impairments that could interfere with participation in the program;\n  3. teachers and students from English-medium or English-version schools;\n  4. individuals unwilling or unable to provide voluntary informed consent\u002Fassent or to complete the full program;\n  5. those who had previously attended any emotional intelligence training program; and\n  6. Students identified as belonging to higher EI profiles (e.g., emotionally competent or well-adjusted groups) based on latent profile analysis (LPA) of Trait Emotional Intelligence scores.\n\n     \\-","12 Years","17 Years",{"count":325,"type":19},80,[22],"The present study examined the effects of an emotional intelligence (EI)-based training program on emotional intelligence and mental health outcomes among secondary school teachers and students in Dhaka City, Bangladesh.\n\nThe study addressed whether the EI-based intervention improves emotional intelligence and reduces psychological distress, including anxiety and depression, while enhancing overall wellbeing (emotional, social, and psychological).\n\nA quasi-experimental design was employed, comparing participants who received a structured EI training program with a control group. The intervention was based on Goleman's mixed model of emotional intelligence, focusing on four core domains: self-awareness, self-management, social awareness, and relationship management.\n\nParticipants were assessed at multiple time points using standardized measures of emotional intelligence, anxiety, depression, and mental health continuum. The study also incorporated a follow-up assessment to examine outcomes over time.\n\nThe findings aim to contribute to understanding the role of emotional intelligence in promoting mental health and to inform school-based psychological intervention strategies.",[283,177,175,284],[286,284,177,175,330],"Latent Profile Analysis","2026-05-12",{"date":333,"type":35},"2026-05-15",{"date":335,"type":35},"2025-04-30",{"date":337,"type":19},"2026-09",{"name":295,"class":42},{"id":340,"slug":4,"hasResults":11,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":344,"eligibilityCriteria":345,"healthyVolunteers":51,"sex":15,"minAge":255,"maxAge":227,"enrollmentInfo":346,"targetDuration":4,"studyType":20,"phases":348,"briefSummary":349,"conditions":350,"keywords":354,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":43},"100639597","NCT07591064","Effectiveness of Positive Deviance\u002FHearth in Treating Uncomplicated Moderate Acute Malnutrition in Children 6-59 Months in Mymensingh Division, Bangladesh","The Effectiveness of Positive Deviance\u002FHearth (PDH), a Local Dietary Approach, to Treat Uncomplicated Moderate Acute Malnutrition (MAM) in Children 6-59 Months in Mymensingh, Bangladesh","PD\u002FHearth MAM","Inclusion Criteria:\n\n* Children 6-52.9 months at Baseline. This is so that children are 6-59 months by end of study (6-7 months from baseline)\n* Children with MAM (WHZ\u002FWLZ \\\u003C-2 and ≥-3 and\u002For MUAC \\\u003C125mm and ≥115mm)\n* No Medical Complications (passes IMCI screening questions)\n* No oedema\n* Child does not deteriorate to SAM (WHZ\u002FWLZ\\\u003C-3 and\u002For MUAC\\\u003C115mm) because child should be referred to health centre\n* Caregiver refuses to receive age-appropriate immunization, Vitamin A and deworming minimum 2 weeks before PDH begins\n* Child is not planning to live outside the study area routinely for more than 2 weeks during the 3 months of the study\n* Written\u002FOral consent is given by Parent\u002FCaregiver to participate in the study\n\nExclusion Criteria:\n\n* Child is not between 6-52 months of age at Baseline\n* Child does not meet the inclusion criteria for WHZ\u002FWLZ and\u002For MUAC; (WHZ\u002FWLZ \\\u003C-2SD and ≥-3SD and\u002For MUAC \\\u003C125mm and ≥115mm);\n* Child has oedema;\n* Child has medical complications and\u002For does not pass the IMCI screening including fever, nausea\u002Fvomiting, acute respiratory illness (refer to Study Protocol V2.0, 19 Feb 2026);\n* Deteriorates to SAM and must be removed from the study and referred to the health centre for specially formulated food (SFF) treatment;\n* Refuses to receive minimum 2 weeks before the intervention begins, age-appropriate immunization and Vitamin A and deworming in the past 6 months;\n* Child lives outside the study area routinely or will be outside of the study area for more than 2 weeks in the upcoming 3 months\n* Parent\u002FCaregiver unable or unwilling to attend PDH from start;\n* Parent\u002FCaregiver does not provide written or oral consent to screen for the trial;\n* Parent\u002FCaregiver does not provide informed consent for the study; and\n* any other reason.",{"count":347,"type":19},400,[22],"The goal of this clinical trial (cluster randomized controlled trial) is to learn whether a Positive Deviance\u002FHearth (PDH) intervention can effectively treat moderate acute malnutrition (MAM) and reduce relapse compared to standard care in children aged 6-59 months diagnosed with MAM in Bangladesh. The main questions it aims to answer are:\n\n* Does the PDH intervention improve recovery rates among children with MAM?\n* Does the PDH intervention reduce relapse to MAM or progression to severe acute malnutrition (SAM) after recovery?\n\nResearchers will compare communities receiving the PDH intervention to communities receiving standard nutrition care (e.g., usual counseling or supplementary feeding programs) to see if PDH leads to better nutritional recovery and sustained outcomes.\n\nParticipants will:\n\n* Take part in a 12-day \"Hearth\" nutrition education program where caregivers prepare and feed children nutrient-dense meals using local foods\n* Receive 2 weeks of home follow-up visits by volunteers after the Hearth sessions, along with ongoing growth monitoring and counseling twice per month\n* Undergo periodic anthropometric assessments (weight, height\u002Flength, Mid-upper arm circumference (MUAC)) at key time points",[351,352,353],"Moderate Acute Malnutrition (MAM)","Undernutrition","Wasting",[355,356,357,358],"Moderate acute malnutrition (MAM)","Children","relapse","positive deviance\u002Fhearth","2026-05-08",{"date":333,"type":35},{"date":362,"type":19},"2026-05-16",{"date":364,"type":19},"2026-12-17",{"name":366,"class":42},"World Vision US",{"id":368,"slug":4,"hasResults":11,"nctId":369,"briefTitle":370,"officialTitle":371,"acronym":4,"eligibilityCriteria":372,"healthyVolunteers":51,"sex":15,"minAge":16,"maxAge":373,"enrollmentInfo":374,"targetDuration":4,"studyType":20,"phases":375,"briefSummary":376,"conditions":377,"keywords":382,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":390,"completionDateStruct":391,"leadSponsor":393,"locationsCount":43},"100637154","NCT07578402","Effect of Digestive Enzymes as Add on Therapy on Patients With Functional Dyspepsia.","Effect of Digestive Enzymes as Add on Therapy on Patients With Functional Dyspepsia - A Randomised, Open Label Trial","Inclusion Criteria:\n\n* Age 18 years or more\n* Patients with FD diagnosed according to ROME IV criteria\n\nExclusion Criteria:\n\n* Structural lesion in endoscopy and positive H. pylori status\n* History of malignancy, liver and biliary tract disease, diabetes mellitus, chronic kidney disease, thyroid disorders\n* Psychiatric disorders\n* Previous history gastrointestinal surgery\n* Any history of hypersensitivity, adverse effect, or ineffectiveness with digestive enzyme\n* Pregnancy and breastfeeding.","70 Years",{"count":279,"type":19},[118],"The goal of this clinical trial is to assess the effect of digestive enzymes in improving dyspeptic symptoms in patients with functional dyspepsia. It will also assess about the safety of drug by recording the patient reported adverse events. The main questions it aims to answer are:\n\nDoes drug digestive enzymes has any effect on patients with functional dyspepsia? What medical problems do participants have when taking drug digestive enzymes? Researcher will compare drug digestive enzymes to a control group taking standard first line treatment only.\n\nParticipants will:\n\nTake drug digestive enzymes 325 milligrams 3 times daily, every day for 4 weeks along with standard first line treatment. A second group will be taken as control arm who will be kept on standard first line treatment only for 4 weeks. They will visit the hospital 2 weekly, and their symptoms will be assessed by a 5-point Likert Scale at baseline, week 2 and 4. Additionally, patient reported adverse events will be documented.",[378,379,380,381],"Dyspepsia","Functioanl Dyspepsia","Epigastric Pain Syndrome","Epigastric Fullness",[378,383,384,385,386],"Post parendial distress syndrome (PPDS)","Epigastric pain syndrome (EPS)","Functional dyspepsia (FD)","Disorder of gut brain interaction (DGBI)","2026-05-05",{"date":389,"type":35},"2026-05-11",{"date":333,"type":19},{"date":392,"type":19},"2027-02-28",{"name":394,"class":42},"Rakibul Mostafa",{"id":396,"slug":4,"hasResults":11,"nctId":397,"briefTitle":398,"officialTitle":398,"acronym":4,"eligibilityCriteria":399,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":277,"enrollmentInfo":400,"targetDuration":4,"studyType":20,"phases":401,"briefSummary":403,"conditions":404,"keywords":406,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":43},"100593576","NCT07008235","Effect of Amitriptyline and Trifluoperazine on Patients With Functional Dyspepsia","Inclusion Criteria:\n\n* Age 18 years or more\n* Patients with symptoms of dyspepsia for duration consisted with ROME IV criteria\n* Patients who are willing to sign informed written consent\n\nExclusion Criteria:\n\n* Structural lesion in Upper GI endoscopy and\u002For positive CLO test\n* Patients scoring 1 or 2 on the 5-point Likert scale for all four dyspepsia symptoms\n* History of malignancy, significant liver and biliary tract disease, hypertension, diabetes mellitus, chronic kidney disease, thyroid disorder, major psychiatric disorders\n* Previous history of gastrointestinal surgery\n* Patients those have to take any drug for other medical condition that may cause dyspepsia, can interfere or whose co-prescription is contraindicated with amitriptyline or trifluoperazine\n* Any patient with ongoing treatment with antidepressants or antipsychotics\n* Any history of hypersensitivity, adverse effect, or ineffectiveness with amitriptyline or trifluoperazine\n* Patients for whom Amitriptyline and Trifluoperazine are contraindicated\n* Elderly patients\\> 60 years\n* Pregnancy and breastfeeding",{"count":279,"type":19},[402,87],"PHASE2","The goal of this clinical trial is to assess and compare the effect of amitriptyline and trifluoperazine in improving dyspeptic symptoms in patients with functional dyspepsia. It will also assess about the safety of drugs amitriptyline and trifluoperazine by recording the patient reported adverse events. The main questions it aims to answer are:\n\nDoes drug amitriptyline and trifluoperazine has any effect on patients with functional dyspepsia? What medical problems do participants have when taking drug amitriptyline and trifluoperazine? Researcher will compare drug amitriptyline and trifluoperazine to a control group taking standard first line treatment only.\n\nParticipants will:\n\nTake drug amitriptyline 10 milligrams at night or trifluoperazine 1 milligrams twice daily every day for 8 weeks along with standard first line treatment. A third group will be taken as control arm who will be kept on standard first line treatment only for 8 weeks. After that all three groups will be kept only on standard first line treatment for an additional 4 weeks. They will visit the hospital 4 weekly, and their symptoms will be assessed by a 5-point Likert Scale at baseline, week 4, 8, and 12. Additionally, patient reported adverse events will be documented.",[405],"Functional Dyspepsia",[405,407,408,409,410,411,412,413,414,415,416,378],"Amitriptyline","Trifluoperazine","Neuromodulator","DGBI","Disorders of Gut Brain Interaction","ROME IV","5-point Likert Scale","Tricyclic antidepressant","Phenothiazine","Antipsychotic","2026-05-04",{"date":419,"type":35},"2026-05-07",{"date":421,"type":35},"2025-07-01",{"date":423,"type":19},"2026-06",{"name":425,"class":42},"Md. Moktadirul Hoque Shuvo",{"id":427,"slug":4,"hasResults":11,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":4,"eligibilityCriteria":431,"healthyVolunteers":11,"sex":15,"minAge":432,"maxAge":433,"enrollmentInfo":434,"targetDuration":4,"studyType":20,"phases":436,"briefSummary":437,"conditions":438,"keywords":440,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":442,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":448,"locationsCount":43},"100627633","NCT07451171","Comparative Efficacy of Antibiotics for Small Intestine Bacterial Overgrowth in Bangladeshi Children","A Phase II Trial to Prevent Linear Growth Stunting and Malnutrition in Impoverished Children From a Low-Income Country by Treating Small Intestine Bacterial Overgrowth","Inclusion Criteria:\n\n* Positive glucose hydrogen breath test (GHBT)\n* Weight-for-age Z score \\> -1\n* Length-for-age Z score \\> -1\n\nExclusion Criteria:\n\n* Presence of known chronic or congenital illness, including developmental delay\n* Presence of acute gastrointestinal illness in the preceding 14 days\n* Antibiotic use in the preceding 14 days\n* Previous adverse reaction to any of the three study medications or other drugs in the same antibiotic classes\n* Sibling previously enrolled in this study","1 Year","2 Years",{"count":435,"type":19},60,[402],"The purpose of this Phase IIa study is to identify the most effective antibiotic regimen to treat small intestine bacterial overgrowth (SIBO) in impoverished Bangladeshi children.",[439],"Small Intestine Bacterial Overgrowth",[441],"environmental enteric dysfunction",{"date":443,"type":35},"2026-05-06",{"date":445,"type":35},"2026-04-18",{"date":447,"type":19},"2026-09-01",{"name":270,"class":42},{"id":450,"slug":4,"hasResults":11,"nctId":451,"briefTitle":452,"officialTitle":453,"acronym":454,"eligibilityCriteria":455,"healthyVolunteers":51,"sex":168,"minAge":322,"maxAge":323,"enrollmentInfo":456,"targetDuration":4,"studyType":202,"phases":4,"briefSummary":458,"conditions":459,"keywords":467,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":476,"completionDateStruct":478,"leadSponsor":480,"locationsCount":43},"100635631","NCT07555197","Association of Seafood Consumption and Nutritional Status Among Adolescent Girls","Association of Seafood Consumption and Nutritional Status Among Adolescent Girls Living in Different Aquatic Ecological Zones in Southwestern Bangladesh","AQUAFOOD","Inclusion Criteria:\n\n* Adolescent girls aged between 12-16 years\n* Residing in the same study area as the 2017 IMMANA study\n* Willing to participate and provide informed consent\n\nExclusion Criteria:\n\n* Any health condition that may affect anthropometric measurements\n* Severe illness that may interfere with physical or biochemical assessments",{"count":457,"type":19},300,"This study examines how seafood consumption, social changes, and climate change affect the nutrition and well-being of adolescent girls in south-western Bangladesh. Many adolescent girls face poor nutrition, early marriage, and limited access to adequate diets. Adolescent girls have high nutritional needs due to growth and potential early motherhood. Seafood, including fish, shrimp, and prawns, provides important nutrients such as omega-3 fatty acids, but little is known about how its consumption relates to nutritional status in this population.\n\nThe study will collect new data from adolescent girls in the same area as a 2017 study (IMMANA study), assessing dietary pattern, nutritional status, socioeconomic conditions, and female autonomy. It will also explore how climate change affects household food access and nutrition to provide policies linking food systems and public health.",[460,461,462,463,464,465,466],"Nutritional Status","Omega 3 Fat Status","Micronutrient Status","Fish Consumption","Dietary Pattern","Female Autonomy","Climate Change",[468,469,470,471,472,473],"Adolescent nutrition","Aquaculture","Climate change","Fish consumption","Female autonomy","Nutritional status","2026-04-30",{"date":443,"type":35},{"date":477,"type":19},"2026-04-25",{"date":479,"type":19},"2026-12-15",{"name":481,"class":42},"University of Copenhagen",{"id":483,"slug":4,"hasResults":11,"nctId":484,"briefTitle":485,"officialTitle":486,"acronym":454,"eligibilityCriteria":487,"healthyVolunteers":51,"sex":15,"minAge":488,"maxAge":489,"enrollmentInfo":490,"targetDuration":433,"studyType":202,"phases":4,"briefSummary":492,"conditions":493,"keywords":498,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":506,"startDateStruct":507,"completionDateStruct":509,"leadSponsor":511,"locationsCount":43},"100634596","NCT07541742","Health and Nutritional Outcomes Among Young Females and Children in Southwest Bangladesh","Health and Nutritional Outcomes Among Young Females and Children in Southwest Bangladesh: A Cohort Study","Inclusion Criteria:\n\n* Young women aged 22-27 years who previously participated in the 2017 study. See study description.\n* If the women has a child age between 6 months to 5 years, the child child is included to be assessed\n\nExclusion Criteria:\n\n* Participants with serious health conditions that may interfere with study procedures or data collection.","5 Months","27 Years",{"count":491,"type":19},240,"This study aims to examine how societal and climate changes influence the nutritional status and fish consumption of young women over a 10 year period in southern Bangladesh, and how these factors affect their children's health. A cohort of 240 adolescents first studied in 2017 will be followed to assess changes in their dietary patterns, nutritional status, climate perceptions and mitigation practices, as well as the nutritional status of their children aged 6 months to 5 years.\n\nThe study in 2017 sampled 60 adolescent girls in each of four rural communities, plus a semi-rural community around a fish processing plant, representing in total 5 communities. Of these 60 X 5 = 300 girls, the current study follows up the individuals in the rural communities representing a cohort of 240.\n\nBangladesh faces high rates of adolescent malnutrition, with many girls married before 18 and suffering from chronic nutrient deficiencies. These issues have long-term impacts on health, productivity, and intergenerational well-being. By linking the fisheries and aquaculture sector, a key to Bangladesh's economy with public health and nutrition, this research aims to guide targeted policies for vulnerable coastal communities.",[460,462,461,494,495,496,497],"Diet Diversity","Markers of Inflammation","Climate Adaptation","Climate Change Awareness",[499,500,501,502,503,504,505],"Aquatic foods","adolescent nutrition","fish intake assessment","dietary biomarkers","climate adaptation","intergenerational nutrition","Bangladesh",{"date":443,"type":35},{"date":508,"type":19},"2026-04-15",{"date":510,"type":19},"2026-12-10",{"name":481,"class":42},{"id":513,"slug":4,"hasResults":11,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":517,"eligibilityCriteria":518,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":277,"enrollmentInfo":519,"targetDuration":4,"studyType":20,"phases":521,"briefSummary":522,"conditions":523,"keywords":530,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":534,"startDateStruct":535,"completionDateStruct":536,"leadSponsor":538,"locationsCount":43},"100635473","NCT07553143","Effect of Preoperative Melatonin on Quality of Recovery After Elective Laparoscopic Cholecystectomy","Effect of Preoperative Melatonin on Quality of Recovery After Elective Laparoscopic Cholecystectomy: A Randomized Controlled Trial","MEL-REC","Inclusion Criteria:\n\n* Age 18-60 years\n* American Society of Anesthesiologists (ASA) physical status I-II\n* Scheduled for elective laparoscopic cholecystectomy under general anesthesia\n* Able to understand and provide informed consent\n* Willing to participate in the study and complete follow-up assessments\n* Body mass index (BMI) 18-35 kg\u002Fm2\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to melatonin or placebo component\n* Chronic use of opioids, sedatives, or hypnotics (regular use for ≥4 weeks prior to surgery)\n* Current use of beta-adrenergic receptor antagonists (beta-blockers) (suppress endogenous melatonin secretion via inhibition of pineal β₁-adrenergic receptors)\n* History of psychiatric disorders requiring ongoing pharmacological treatment\n* Pregnancy or lactation\n* Severe hepatic impairment (Child-Pugh class B or C), as melatonin undergoes extensive first-pass hepatic metabolism via CYP1A2\n* Diagnosed obstructive sleep apnoea requiring continuous positive airway pressure\n* Diagnosed circadian rhythm disorder (e.g., delayed sleep phase disorder, advanced sleep phase disorder) requiring medical management\n* Use of exogenous melatonin supplements within 30 days prior to surgery\n* Inability to complete study questionnaires due to language barrier or cognitive impairment\n* History of substance abuse or dependence",{"count":520,"type":19},84,[22],"Laparoscopic cholecystectomy is one of the most commonly performed abdominal surgical procedures worldwide. Although the widespread implementation of Enhanced Recovery after Surgery (ERAS) protocols has improved perioperative outcomes, many patients continue to experience postoperative pain, sleep disturbance, anxiety, nausea, and fatigue, symptoms that collectively impair overall quality of recovery (QoR). Melatonin, an endogenous hormone that regulates circadian rhythm, also possesses anxiolytic, analgesic, antioxidant, and anti-inflammatory properties, positioning it as a valuable perioperative adjunct. However, most previous studies have evaluated melatonin primarily for isolated outcomes such as sleep quality or anxiety. Its effect on comprehensive postoperative recovery, assessed using validated patient-reported outcome instruments, remains insufficiently explored, particularly in laparoscopic cholecystectomy populations and in South Asian clinical settings.\n\nThis prospective, randomized, double-blind, placebo-controlled trial (the MEL-REC trial) aims to evaluate the effect of preoperative oral melatonin on postoperative quality of recovery in patients undergoing elective laparoscopic cholecystectomy under general anaesthesia. The study will be conducted in the Department of Anaesthesiology at Combined Military Hospital (CMH), Dhaka, Bangladesh, over a total study period of 18 months (January 2026 to June 2027), with patient recruitment planned for 8 months (May to December 2026) after taking approval from institutional review board. Eighty four adult patients aged 18-60 years with American Society of Anesthesiologists (ASA) physical status I-II will be randomly allocated in a 1:1 ratio into two equal groups (n = 42 per group) using computer-generated permuted block randomization with centralized pharmacy based allocation concealment. The melatonin group (Group M) will receive oral melatonin 6 mg administered 60 minutes before induction of anaesthesia and the placebo group (Group P) will receive an identical placebo tablet under the same conditions. Neither the participants, the treating anaesthesiologist, the outcome assessor, nor the data analyst will be aware of group allocation until database lock. All patients will receive a standardized anaesthesia and perioperative management protocol, including standardized postoperative analgesia.\n\nThe primary outcome will be postoperative quality of recovery assessed using the Quality of Recovery-15 (QoR-15) score at 24 ± 2 hours after surgery. Secondary outcomes include postoperative sleep quality measured by the Richards-Campbell Sleep Questionnaire, change in preoperative anxiety (delta-VAS-A score), total opioid consumption during the first 24 hours expressed as intravenous morphine milligram equivalents, incidence of postoperative nausea and vomiting, and time to first rescue analgesic request. All postoperative outcomes will be assessed by a trained research assistant blinded to group allocation.\n\nBased on the available evidence, it is anticipated that patients receiving preoperative melatonin will demonstrate higher QoR-15 scores at 24 hours after surgery compared with the placebo group. The melatonin group is also expected to have improved postoperative sleep quality, reduced opioid consumption, and a greater reduction in preoperative anxiety.\n\nIf a clinically meaningful benefit is confirmed, given its well established safety profile, low cost, and ease of oral administration, preoperative melatonin may represent a practical perioperative adjunct that can be readily incorporated into ERAS protocols for laparoscopic cholecystectomy. The trial will be prospectively registered in the Bangladesh Medical Research Council (BMRC) clinical trial registry or clinicaltrials.gov prior to recruitment.",[524,525,526,527,528,529],"Laparoscopic Cholecystectomy","Postoperative Quality of Recovery","Preoperative Anxiety","Postoperative Sleep Quality","Opioid Consumption, Postoperative","PONV in Laparoscopic Cholocystectomies",[525,531,532,524],"QoR-15","Melatonin","2026-04-29",{"date":387,"type":35},{"date":157,"type":19},{"date":537,"type":19},"2027-06-30",{"name":539,"class":42},"Armed Forces Medical Institute Bangladesh",{"id":541,"slug":4,"hasResults":11,"nctId":542,"briefTitle":543,"officialTitle":544,"acronym":545,"eligibilityCriteria":546,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":547,"targetDuration":4,"studyType":20,"phases":549,"briefSummary":550,"conditions":551,"keywords":557,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":566,"lastUpdatePostDateStruct":567,"startDateStruct":568,"completionDateStruct":570,"leadSponsor":572,"locationsCount":574},"100543973","NCT06362837","Evaluation of REACTS-IN, an Intervention to Improve Nutrition, Hygiene, and Sexual and Reproductive Health Services","Realizing Gender Equality, Attitudinal Change & Transformative Systems in Nutrition (REACTS-IN)","REACTS-IN","Inclusion Criteria:\n\n(i)Women:\n\n* 15-49 y of age\n* biological mother of child in the home who is 0-5.9, 6-23.9, or 24-59.9 months\n* has lived in the community for at 12 months\n\n(ii) Husbands\u002Fpartners:\n\n* no age limit\n* lives in the home with index woman\n* has lived in community for at least 12 months\n\n(iii) Adolescents:\n\n* 10-19 years\n* male or female\n* has been in target school for at least 6 months\n* lives in the target community\n\n(iv) Children:\n\n* 0-5.9, 6-23.9, or 24-59.9 months\n\nExclusion Criteria:\n\n(i) Children:\n\n* no limitation on normal diet or growth (birth defects, illnesses)",{"count":548,"type":19},13500,[22],"This is an independent evaluation of World VIsion's 7-year quasi-experimental intervention to improve nutrition, nutrition-related rights and gender equality for women, adolescent girls, and children under five years of age in rural Bangladesh, Kenya, and Tanzania. The evaluation will collect baseline, midline, and end-line data from intervention communities, schools, and health facilities. Only baseline and endline will be collected on the comparison communities. The evaluation objectives are to test if the intervention improved indicators for (i) child anthropometry, (ii) maternal and child dietary practices, (iii) women's empowerment, and (iv) equitable health service access for nutrition and sexual and reproductive needs. The evaluation analysis will take into account gender differences in the indicators.",[552,553,554,555,556],"Stunting","Gender Equality","Acceptability of Health Care","Diet; Deficiency","Empowerment",[558,559,560,561,562,563,564,565],"nutrition","gender equity","health services","sexual and reproductive rights","dietary diversity","anthropometry","sexual and reproductive health services","WASH","2026-04-27",{"date":533,"type":35},{"date":569,"type":35},"2024-09-01",{"date":571,"type":19},"2029-12-31",{"name":573,"class":42},"McGill University",3,{"id":576,"slug":4,"hasResults":11,"nctId":577,"briefTitle":578,"officialTitle":579,"acronym":580,"eligibilityCriteria":581,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":582,"enrollmentInfo":583,"targetDuration":4,"studyType":20,"phases":585,"briefSummary":586,"conditions":587,"keywords":589,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":566,"lastUpdatePostDateStruct":596,"startDateStruct":597,"completionDateStruct":599,"leadSponsor":601,"locationsCount":43},"100506886","NCT05880212","Implementation of the Specific Treatment Of Problems of the Spine Approach in Bangladesh","Implementation of the Specific Treatment Of Problems of the Spine (STOPS) Approach in Bangladesh: A Prospective Sequential Comparison","STOPS-Bangla","Inclusion Criteria:\n\nPhysiotherapists:\n\nQualified physiotherapists and physiotherapy assistants in Bangladesh who are involved in low back pain management and working in either or both trial settings will provide the treatment in phases 1 and 3. To be eligible, physiotherapists and physiotherapy assistants must be willing to participate in all phases of the trial (Phases I, II, and III). They must have completed the organised STOPS training course led by the original Australian developers (Jon Ford and Andrew Hahne), where the assessment and treatment protocols will be taught in Phase II.\n\nPatients:\n\n1. A primary complaint of either:\n\n   1. low back pain, defined as pain between the inferior costal margin and the inferior gluteal fold with or without referral into the leg(s)\n\n      or\n   2. referred leg pain, defined as predominately unilateral posterior leg pain extending below the knee, or anterior thigh pain, with or without back pain\n2. Duration of the current episode of primary complaint lasting for greater than 3 months (chronic stage of the injury)\n3. Aged between 18 and 65 (inclusive)\n4. Fluency in English or Bengali sufficient to complete questionnaires and to enable understanding of the intervention\n5. Agreeing to refrain from other interventions wherever possible for the 10-week treatment period of the trial, aside from consultations with medical practitioners, medication, and any exercises already being undertaken\n\nExclusion Criteria:\n\nPhysiotherapist:\n\nNot willing to participate in the study for all 3 phases.\n\nPatient:\n\n1. Red flag pathologies such as active cancer under current treatment, risk of spinal fracture, signs of potential infection, and major systemic inflammatory disease.\n2. Signs of cauda equina syndrome based on bladder or bowel disturbance and\u002For imaging\n3. Current pregnancy, or childbirth within the last 6 months, as this could impair the ability to undertake exercises, and could also cause back and leg symptoms that are not related to the subgroups under investigation\n4. Spinal injections within the last 6 weeks, as we wish to study treatment effects independent of the effects of injections\n5. Any history of lumbar spine surgery, as there is already considerable research evaluating the efficacy of post-surgical rehabilitation programs\n6. A pain intensity score of less than 2\u002F10 on the numerical pain rating scale due to low severity.\n7. Minimal activity limitation, evidenced by a baseline ability to perform ALL of (walk, sit, and stand for one hour or more and no sleep disturbance at night), as we wish to exclude people with low severity.\n8. Inability to walk safely, such as severe foot drop causing regular tripping, as the interventions in the trial include walking for most participants.\n9. Planned absence of more than one week during the treatment period (such as holidays).","65 Years",{"count":584,"type":19},154,[22],"The goal of this implementation trial is to evaluate the clinical outcomes associated with usual physiotherapy care compared to individualized physiotherapy in accordance with the Specific Treatment of Problems of the Spine (STOPS) approach in patients with chronic low back pain (CLBP). The main questions it aims to answer are:\n\n* Is the STOPS approach more effective than usual care physiotherapy among patients with CLBP?\n* Is STOPS physiotherapy cost-effective compared to usual physiotherapy care for patients with CLBP.\n* Does STOPS training improve the quality of care among Bangladeshi physiotherapists?",[588],"Chronic Low-back Pain",[590,591,592,593,594,505,595],"Chronic low back pain","Physiotherapy","Usual care","STOPS","Implementation trial","Physiotherapist",{"date":417,"type":35},{"date":598,"type":35},"2023-08-01",{"date":600,"type":19},"2026-06-30",{"name":602,"class":42},"Mohammad Ali",{"id":604,"slug":4,"hasResults":11,"nctId":605,"briefTitle":606,"officialTitle":607,"acronym":4,"eligibilityCriteria":608,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":609,"enrollmentInfo":610,"targetDuration":4,"studyType":20,"phases":612,"briefSummary":613,"conditions":614,"keywords":618,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":622,"lastUpdatePostDateStruct":623,"startDateStruct":624,"completionDateStruct":626,"leadSponsor":628,"locationsCount":43},"100636021","NCT07560267","Efficacy of Ultrasound-Guided Erector Spinae Block for Postoperative Pain Management in Nephrectomy","Efficacy of Ultrasound-Guided Erector Spinae Plane Block in Postoperative Pain Management in Nephrectomy: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adult patients aged 18 to 64 years\n* Scheduled for open nephrectomy (radical or partial) under general anesthesia\n* ASA physical status I-II (American Society of Anesthesiologists classification)\n\nExclusion Criteria:\n\n* Allergy to local anesthetics.\n* Local infection or inflammation at the site of the Block placement.\n* Presence of anatomical deformities in the spine\n* Coagulopathy or any bleeding disorder.\n* Pregnancy or breastfeeding women.\n* History of severe chronic pain syndrome","64 Years",{"count":611,"type":19},66,[22],"This clinical trial aims to evaluate the effectiveness of the ultrasound-guided erector spinae plane (ESP) block in managing postoperative pain for patients undergoing open nephrectomy (kidney removal surgery). The study will compare this new technique to traditional pain management methods, such as opioid medications, to assess whether the ESP block reduces pain and the need for opioids after surgery.\n\nPatients will be randomly assigned to one of two groups:\n\nGroup C will receive conventional pain relief methods, including opioids. Group E will receive the ultrasound-guided ESP block in addition to general anesthesia.\n\nThe main goals are to determine:\n\nHow much pain relief each method provides, measured using a visual analog scale (VAS).\n\nThe total amount of opioids required during the first 24 hours post-surgery.\n\nAdditional measurements will include monitoring vital signs like heart rate, blood pressure, and oxygen levels.\n\nThis study will help find safer and more effective ways to manage pain after nephrectomy, reducing the reliance on opioids and improving patient recovery",[615,616,617],"Erector Spinae Plane Block","Nephrectomy","Postoperative Pain",[619,620,621,616],"Erector Spinae Plane Block (ESP)","Postoperative Pain Management","Opioid Consumption","2026-04-24",{"date":157,"type":35},{"date":625,"type":35},"2025-09-01",{"date":627,"type":19},"2026-07-30",{"name":161,"class":42},{"id":630,"slug":4,"hasResults":11,"nctId":631,"briefTitle":632,"officialTitle":633,"acronym":4,"eligibilityCriteria":634,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":635,"targetDuration":4,"studyType":20,"phases":636,"briefSummary":637,"conditions":638,"keywords":643,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":649,"startDateStruct":651,"completionDateStruct":652,"leadSponsor":654,"locationsCount":656},"100634280","NCT07537634","Vonoprazan-based Versus Esomeprazole-based Triple Therapy for Helicobacter Pylori Eradication","Comparison Between Vonoprazan-Based Triple Therapy and Esomeprazole-Based Triple Therapy for Eradication of Helicobacter Pylori Infection: An Open-Label Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Dyspeptic patients with positive for both rapid urease test and stool antigen test\n3. Patients giving written informed consent\n\nExclusion Criteria:\n\n1. Treatment with a proton pump inhibitor, H2-receptor antagonist within the last 2 weeks, prior to the study\n2. Treatment with antibiotics or bismuth preparation within 4 weeks prior to the study\n3. Previous H. pylori eradication therapy\n4. Gastric or duodenal ulcer with current or recent bleeding on endoscopy\n5. Significant upper or lower gastrointestinal bleeding within 4 weeks\n6. Patients with regular intake of NSAIDs or steroids\n7. Surgery that might affect gastric acid secretion e.g., upper GI resection or vagotomy\n8. Known case of malignancy, including MALToma\n9. Advanced co-morbidities (e.g., CLD, CKD, cardio-respiratory failure, known thyroid disease)\n10. Chronic alcohol abuse, chronic illegal drug use, or drug addiction within the past 12 months\n11. Pregnant, lactating woman or intend to become pregnant within the study period\n12. History of hypersensitivity to vonoprazan, PPIs, amoxicillin, and\u002For levofloxacin\n13. On colchicine\n14. Subjects with abnormal laboratory test at the start of the screening period:\n\nS. creatinine \\> 2 mg\u002Fdl SGPT \\> 2 x Upper limit of normal",{"count":325,"type":19},[118],"The goal of this clinical trial is to compare the efficacy and safety of vonoprazan-based levofloxacin-containing triple therapy with esomeprazole-based levofloxacin-containing triple therapy for eradication of Helicobacter pylori infection in adults with dyspepsia.\n\nThe main questions it aims to answer are whether vonoprazan-based triple therapy achieves a higher eradication rate of H. pylori, whether it provides greater improvement in dyspeptic symptoms, and what adverse effects are associated with each regimen.\n\nResearchers will compare the two treatment regimens to determine which is more effective for H. pylori eradication.\n\nParticipants with confirmed H. pylori infection will be randomly assigned to receive either vonoprazan-based or esomeprazole-based triple therapy for 14 days.\n\nFour weeks after completion of therapy, participants will undergo repeat stool antigen testing to assess eradication.\n\nDrug compliance, adverse effects, and dyspeptic symptom scores will be recorded during follow-up.\n\nParticipants with endoscopic mucosal lesions at baseline will undergo follow-up endoscopy for reassessment.",[639,378,640,641,642],"Helicobacter Pylori Infection","Peptic Ulcer Disease","Helicobacter Pylori","H Pylori",[644,645,646,647,30,648,378],"Helicobacter pylori","Helicobacter pylori eradication","Vonoprazan","Esomeprazole","Triple therapy",{"date":650,"type":35},"2026-04-22",{"date":508,"type":19},{"date":653,"type":19},"2026-08-14",{"name":655,"class":42},"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",2,{"id":658,"slug":4,"hasResults":11,"nctId":659,"briefTitle":660,"officialTitle":661,"acronym":662,"eligibilityCriteria":663,"healthyVolunteers":11,"sex":15,"minAge":664,"maxAge":4,"enrollmentInfo":665,"targetDuration":4,"studyType":20,"phases":667,"briefSummary":668,"conditions":669,"keywords":677,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":508,"lastUpdatePostDateStruct":681,"startDateStruct":683,"completionDateStruct":685,"leadSponsor":687,"locationsCount":689},"100634728","NCT07543458","Therapeutics for Moderate and Severe Dengue","A Randomised Platform Trial to Evaluate Therapeutics in Patients With Moderate or Severe Dengue (DEN-HOST)","DEN-HOST","Inclusion Criteria:\n\n* Age ≥5 years\n* Decision to hospitalise\n* Clinical diagnosis of dengue\n* Participants must also have at least one of the following:\n\n  1. Severe abdominal pain or tenderness\n  2. Vomiting more than 3 times in the past 24 hours\n  3. Pleural effusion or ascites on clinical or radiological examination\n  4. Absolute haematocrit \\>50%\n  5. 15% increase in haematocrit compared with a baseline sample (defined as the first sample taken during the current illness)\n  6. Absolute platelet count \\\u003C50 × 10⁹\u002FL\n  7. Absolute platelet count \\\u003C100 × 10⁹\u002FL AND a drop \\>50 × 10⁹\u002FL in the past 32 hours\n  8. ALT or AST \\>400 IU\u002FL\n  9. Pulse pressure \\\u003C20mmHg or hypotension for age AND at least one of: peripheral capillary refill time \\>2 seconds; urine output 0.5ml\u002Fkg\u002Fhr; cold\u002Fclammy peripheries; agitation or altered mental state\n  10. Bleeding leading to hypotension for age or requiring blood transfusion or medical intervention (e.g. surgery, endoscopy, or vasoactive drugs)\n  11. Symptomatic bleeding into a critical site (intracranial, intraspinal, intraocular with visual impairment, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome)\n  12. Requirement for organ support, including vasopressors or inotropes, assisted ventilation, dialysis or haemofiltration, or coma (unresponsive to pain without sedation) or requirement for intravenous antiseizure medications\n\nExclusion Criteria:\n\n* Patients on ≥ day 10 of illness or who are clinically improving in the opinion of the managing doctor (the 'recovery phase') will be excluded from recruitment. Other exclusion criteria are specific to individual treatment comparisons, and do not preclude randomisation to other arms of the study.\n* A participant may not enter a specific treatment comparison if that treatment is considered to be indicated or contraindicated by the responsible clinician.","5 Years",{"count":666,"type":19},8800,[87],"The purpose of this multi-site, factorial randomised, platform trial is to evaluate host-directed therapeutic agents in patients hospitalised with moderate and severe dengue virus infection. Our primary aim is to find safe and affordable therapeutics which prevent disease progression among those at high risk for severe dengue, and improve outcomes for those with established severe disease, thereby also reducing the substantial burden placed on health systems in dengue endemic regions.",[205,670,671,672,673,674,675,676],"Severe Dengue","Mosquito-Borne Diseases","Vector Borne Diseases","Arbovirus Infections","Flavivirus Infections","RNA Virus Infections","Hemorrhagic Fever",[678,679,680],"dengue treatment","host-directed therapy","host-targeted therapeutics",{"date":682,"type":35},"2026-04-21",{"date":684,"type":19},"2026-10-01",{"date":686,"type":19},"2031-07-31",{"name":688,"class":42},"Oxford University Clinical Research Unit, Vietnam",18,{"id":691,"slug":4,"hasResults":11,"nctId":692,"briefTitle":693,"officialTitle":694,"acronym":4,"eligibilityCriteria":695,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":696,"enrollmentInfo":697,"targetDuration":4,"studyType":20,"phases":699,"briefSummary":700,"conditions":701,"keywords":706,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":712,"lastUpdatePostDateStruct":713,"startDateStruct":715,"completionDateStruct":717,"leadSponsor":718,"locationsCount":43},"100600482","NCT07098065","Health Warnings and Counseling for Smoking Cessation","Health Warnings and Counseling at Primary Health Care Centers for Smoking Cessation and NCD Prevention: A Randomized Controlled Trial in Bangladesh and Pakistan","Inclusion Criteria:\n\n* Adults aged 18 and older\n* Adults (≥18 years) who are current smokers (daily or occasional) and regular visitors to participating pharmacies.\n* Permanent resident of the study area,\n* Access to mobile phone\n* Able to operate smartphone or tablet.\n\nExclusion Criteria:\n\n* Without pregnancy and lactation\n* Without cognitive or psychiatric conditions,\n* Without severe medical conditions,\n* Participation in other studies, and inability to consent.","90 Years",{"count":698,"type":19},3400,[22],"Tobacco use remains persistently high across South Asia, despite numerous public health efforts, and continues to significantly contribute to the burden of non-communicable diseases (NCDs) such as cardiovascular disease, hypertension, diabetes, and stroke. Community pharmacists-widely accessible and trusted within their communities-are an underutilized resource for delivering public health interventions. Graphic health warnings (GHWs), recommended by the World Health Organization (WHO), have been shown to promote smoking cessation, but are rarely paired with personalized counseling by healthcare providers.\n\nThis study aims to evaluate both the effectiveness and cost-effectiveness of integrating GHWs with pharmacist-led personalized counseling at primary healthcare pharmacies in Bangladesh and Pakistan. A cluster randomized controlled trial (RCT) will be conducted, enrolling 3,240 adult participants in Bangladesh and \\~160 participants in Pakistan (for feasibility study) from community pharmacies. Participants will be randomly assigned to one of three groups: (1) GHW only (distribution of printed booklets); (2) GHW + counseling (pharmacist-led counselling sessions based on booklets at baseline and six months, with monthly SMS reminders); or (3) standard care (usual pharmacy services with no additional materials).\n\nThe intervention includes twice-yearly counseling sessions-delivered both in-person and digitally-supported by educational booklets and leaflets. The primary outcome is self-reported 7-day point prevalence abstinence at 12 months (validated where feasible). Secondary outcomes include reduction in cigarettes per day, quit attempts, readiness to quit, awareness of tobacco harms, diet and physical activity scores, quality of life, blood pressure control among hypertensive participants, and cost-effectiveness. Feasibility outcomes in Pakistan include recruitment rate, participant retention, intervention fidelity and acceptability. Bayesian statistical models will be used to assess efficacy, and economic evaluations will determine the cost-effectiveness of the interventions. The findings aim to inform scalable public health strategies for tobacco control and NCD prevention in resource-limited settings.",[702,703,704,705],"Tobacco Cessation","Health Warning Label","Hypertension","Non Communicable Chronic Diseases",[707,708,709,710,711],"Tobacco cessation","Graphic health warnings (GHWs)","Non-communicable diseases (NCDs)","Cluster randomized controlled trial (RCT)","Pharmacist-led counseling","2026-04-13",{"date":714,"type":35},"2026-04-14",{"date":716,"type":35},"2026-02-01",{"date":132,"type":19},{"name":719,"class":42},"Hitotsubashi University",""]